CN108324685A - A kind of production technology of flunarizine hydrochloride oral administration solution - Google Patents
A kind of production technology of flunarizine hydrochloride oral administration solution Download PDFInfo
- Publication number
- CN108324685A CN108324685A CN201810403663.6A CN201810403663A CN108324685A CN 108324685 A CN108324685 A CN 108324685A CN 201810403663 A CN201810403663 A CN 201810403663A CN 108324685 A CN108324685 A CN 108324685A
- Authority
- CN
- China
- Prior art keywords
- flunarizine hydrochloride
- oral administration
- solution
- flunarizine
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Abstract
The present invention relates to a kind of production technologies of flunarizine hydrochloride oral administration solution, include the following steps：Step 1：It boils；Step 2：Encapsulation；Technical scheme of the present invention has the following advantages that：Drug is solution state, rapid-action compared to solid pharmaceutical preparation without disintegrating procedue；Be conducive to human body to drug absorption, bioavilability is compared with solid pharmaceutical preparation height；Using purified water as solvent, without other auxiliary materials, reduce interference of the auxiliary material to main ingredient, while also reducing the ill-effect of accessory strips.
Description
Technical field
The present invention relates to flunarizine hydrochloride technical fields, refer specifically to a kind of production work of flunarizine hydrochloride oral administration solution
Skill.
Background technology
Flunarizine hydrochloride is white or off-white color crystallization or crystalline powder；It is odorless, it is tasteless.This product is in methanol or ethyl alcohol
Middle slightly molten, the slightly soluble in chloroform, soluble,very slightly, almost insoluble in benzene in water.The fusing point of fusing point this product is 204~210
DEG C, when melting, decomposes simultaneously.
Solid pharmaceutical preparation, such as tablet, capsule is made in flunarizine hydrochloride.
Flunarizine hydrochloride is insoluble in water, makes solid pharmaceutical preparation there are the interference of more auxiliary material, and tablet, capsule etc., which exist, to be collapsed
Solution is slow, and main ingredient is not easy the defects such as dissolution, bioavilability be low.
Invention content
It is low using conductivity the purpose of the present invention is to provide a kind of production technology of flunarizine hydrochloride oral administration solution
Purified water promotes main ingredient flunarizine hydrochloride to be dissolved in water, flunarizine hydrochloride is made oral at relatively high temperatures as solvent
Pharmaceutical solutions.
To achieve the above object, the present invention provides the following technical solutions, a kind of production of flunarizine hydrochloride oral administration solution
Technique includes the following steps：Step 1：It boils；Step 2：Encapsulation；Wherein：
In step 1, flunarizine hydrochloride is added in suitable purified water, heating keeps boiling stirring 20 ~ 35 after boiling
Minute, it is configured to flunarizine hydrochloride solution；
It is using stud filter element filtering, the flunarizine hydrochloride solution in step 1 is filling in clean brown in step 2
It in vial, seals, sterilizes, detection, packaging is got product.
Further, the purified water in the step 1 is the purified water that conductivity is less than 1.0us/cm.
Further, in the flunarizine hydrochloride solution in the step 1 content of flunarizine hydrochloride in terms of flunarizine
For 0.001g/ml.
Further, the aperture of the stud filter core in the step 2 is less than 0.5 μm.
Compared with prior art, technical scheme of the present invention has the following advantages that：
1, drug is solution state, rapid-action compared to solid pharmaceutical preparation without disintegrating procedue；
2, be conducive to human body to drug absorption, bioavilability is compared with solid pharmaceutical preparation height；
3, using purified water as solvent, without other auxiliary materials, reduce interference of the auxiliary material to main ingredient, while also reducing accessory strips
Ill-effect.
Description of the drawings
Fig. 1 is the process flow chart of the present invention.
Specific implementation mode
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation describes, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.It is based on
Embodiment in the present invention, it is obtained by those of ordinary skill in the art without making creative efforts all other
Embodiment shall fall within the protection scope of the present invention.
The present invention provides a kind of technical solution：A kind of production technology of flunarizine hydrochloride oral administration solution, including following step
Suddenly：Step 1：It boils；Step 2：Encapsulation；Wherein：
In step 1, flunarizine hydrochloride is added in suitable purified water, heating keeps boiling stirring 20 ~ 35 after boiling
Minute, it is configured to flunarizine hydrochloride solution；
It is using stud filter element filtering, the flunarizine hydrochloride solution in step 1 is filling in clean brown in step 2
It in vial, seals, sterilizes, detection, packaging is got product.
Further, the purified water in the step 1 is the purified water that conductivity is less than 1.0us/cm.
Further, in the flunarizine hydrochloride solution in the step 1 content of flunarizine hydrochloride in terms of flunarizine
For 0.001g/ml.
Further, the aperture of the stud filter core in the step 2 is less than 0.5 μm.
Embodiment one：
A kind of production technology of flunarizine hydrochloride oral administration solution, includes the following steps：Step 1：It boils；Step 2：Encapsulation；
Wherein：
In step 1, flunarizine hydrochloride is added in suitable purified water, heating keeps 25 points of boiling stirring after boiling
Clock is configured to flunarizine hydrochloride solution；
It is using stud filter element filtering, the flunarizine hydrochloride solution in step 1 is filling in clean brown in step 2
It in vial, seals, sterilizes, detection, packaging is got product.
Further, the purified water in the step 1 is the purified water that conductivity is less than 1.0us/cm.
Further, the content of flunarizine hydrochloride is 0.12g/ml in the flunarizine hydrochloride solution in the step 1.
Further, the aperture of the stud filter core in the step 2 is less than 0.5 μm.
Embodiment two：
A kind of production technology of flunarizine hydrochloride oral administration solution, includes the following steps：Step 1：It boils；Step 2：Encapsulation；
Wherein：
In step 1, flunarizine hydrochloride is added in suitable purified water, heating keeps 30 points of boiling stirring after boiling
Clock is configured to flunarizine hydrochloride solution；
It is using stud filter element filtering, the flunarizine hydrochloride solution in step 1 is filling in clean brown in step 2
It in vial, seals, sterilizes, detection, packaging is got product.
Further, the purified water in the step 1 is the purified water that conductivity is less than 1.0us/cm.
Further, in the flunarizine hydrochloride solution in the step 1 content of flunarizine hydrochloride in terms of flunarizine
For 0.001g/ml.
Further, the aperture of the stud filter core in the step 2 is less than 0.5 μm.
Embodiment three：
A kind of production technology of flunarizine hydrochloride oral administration solution, includes the following steps：Step 1：It boils；Step 2：Encapsulation；
Wherein：
In step 1, flunarizine hydrochloride is added in suitable purified water, heating keeps 35 points of boiling stirring after boiling
Clock is configured to flunarizine hydrochloride solution；
It is using stud filter element filtering, the flunarizine hydrochloride solution in step 1 is filling in clean brown in step 2
It in vial, seals, sterilizes, detection, packaging is got product.
Further, the purified water in the step 1 is the purified water that conductivity is less than 1.0us/cm.
Further, in the flunarizine hydrochloride solution in the step 1 content of flunarizine hydrochloride in terms of flunarizine
For 0.001g/ml.
Further, the aperture of the stud filter core in the step 2 is less than 0.5 μm.
A kind of production technology of flunarizine hydrochloride oral administration solution, using the low purified water of conductivity as solvent, higher
At a temperature of promote main ingredient flunarizine hydrochloride be dissolved in water, oral solution formulation is made in flunarizine hydrochloride.
Technical scheme of the present invention has the following advantages that：
1, drug is solution state, rapid-action compared to solid pharmaceutical preparation without disintegrating procedue；
2, be conducive to human body to drug absorption, bioavilability is compared with solid pharmaceutical preparation height；
3, using purified water as solvent, without other auxiliary materials, reduce interference of the auxiliary material to main ingredient, while also reducing accessory strips
Ill-effect.
The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention, for this field skill
For art personnel, it is clear that invention is not limited to the details of the above exemplary embodiments, and without departing substantially from the present invention spirit or
In the case of essential characteristic, the present invention can be realized in other specific forms.Therefore, in all respects, should all incite somebody to action
Embodiment regards exemplary as, and is non-limiting, the scope of the present invention by appended claims rather than on state
Bright restriction, it is intended that including all changes that come within the meaning and range of equivalency of the claims in the present invention
It is interior.Any reference signs in the claims should not be construed as limiting the involved claims.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
Understanding without departing from the principles and spirit of the present invention can carry out these embodiments a variety of variations, modification, replace
And modification, the scope of the present invention is defined by the appended.
Claims (4)
1. a kind of production technology of flunarizine hydrochloride oral administration solution, includes the following steps：Step 1：It boils；Step 2：Envelope
Dress；It is characterized in that：
In step 1, flunarizine hydrochloride is added in suitable purified water, heating keeps boiling stirring 20 ~ 35 after boiling
Minute, it is configured to flunarizine hydrochloride solution；
It is using stud filter element filtering, the flunarizine hydrochloride solution in step 1 is filling in clean brown in step 2
It in vial, seals, sterilizes, detection, packaging is got product.
2. a kind of production technology of flunarizine hydrochloride oral administration solution according to claim 1, it is characterised in that：The step
Purified water in rapid one is the purified water that conductivity is less than 1.0us/cm.
3. a kind of production technology of flunarizine hydrochloride oral administration solution according to claim 1, it is characterised in that：The step
The content of flunarizine hydrochloride is 0.12g/ml in flunarizine hydrochloride solution in rapid one.
4. a kind of production technology of flunarizine hydrochloride oral administration solution according to claim 1, it is characterised in that：The step
The aperture of stud filter core in rapid two is less than 0.5 μm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810403663.6A CN108324685A (en) | 2018-04-28 | 2018-04-28 | A kind of production technology of flunarizine hydrochloride oral administration solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810403663.6A CN108324685A (en) | 2018-04-28 | 2018-04-28 | A kind of production technology of flunarizine hydrochloride oral administration solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108324685A true CN108324685A (en) | 2018-07-27 |
Family
ID=62934596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810403663.6A Pending CN108324685A (en) | 2018-04-28 | 2018-04-28 | A kind of production technology of flunarizine hydrochloride oral administration solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108324685A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109326A (en) * | 1994-08-08 | 1995-10-04 | 河南淅川制药厂 | Fuguiqin hydrochloride injection |
| CN1528308A (en) * | 2003-09-27 | 2004-09-15 | 河南淅川制药集团有限公司 | Flunarizine hydro chloride high-capacity injecta and preparing process thereof |
| CN1562028A (en) * | 2004-04-02 | 2005-01-12 | 北京医工生物技术研究所 | Flunarizine hydrochoride injection and preparing method |
| CN1593418A (en) * | 2004-06-30 | 2005-03-16 | 宛六一 | Flunarizine hydrochloride soft capsule and its preparation method |
| CN1615869A (en) * | 2004-10-21 | 2005-05-18 | 南京虹桥医药技术研究所 | Flunarizine hydrochloride injection and its preparing method |
| CN101623298A (en) * | 2009-08-13 | 2010-01-13 | 成都顺道医药开发有限公司 | Preparation method of sodium ascorbyl phosphate oral solution |
| WO2011006073A1 (en) * | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| CN102038704A (en) * | 2009-10-22 | 2011-05-04 | 北京颐悦医药科技有限公司 | Pharmaceutical composition for treating cold in children and preparation method thereof |
| CN106390102A (en) * | 2016-11-30 | 2017-02-15 | 郑州仁宏医药科技有限公司 | Western medicine composition for treating schizophrenia |
| CN107982213A (en) * | 2017-11-30 | 2018-05-04 | 广西壮族自治区农业科学院农产品加工研究所 | A kind of preparation method of banana flowers polysaccharide oral liquid for decreasing blood sugar |
| CN108158990A (en) * | 2018-03-07 | 2018-06-15 | 孙奉生 | The production technology of Pitavastatin Ca oral liquid |
-
2018
- 2018-04-28 CN CN201810403663.6A patent/CN108324685A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109326A (en) * | 1994-08-08 | 1995-10-04 | 河南淅川制药厂 | Fuguiqin hydrochloride injection |
| CN1528308A (en) * | 2003-09-27 | 2004-09-15 | 河南淅川制药集团有限公司 | Flunarizine hydro chloride high-capacity injecta and preparing process thereof |
| CN1562028A (en) * | 2004-04-02 | 2005-01-12 | 北京医工生物技术研究所 | Flunarizine hydrochoride injection and preparing method |
| CN1593418A (en) * | 2004-06-30 | 2005-03-16 | 宛六一 | Flunarizine hydrochloride soft capsule and its preparation method |
| CN1615869A (en) * | 2004-10-21 | 2005-05-18 | 南京虹桥医药技术研究所 | Flunarizine hydrochloride injection and its preparing method |
| WO2011006073A1 (en) * | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| CN101623298A (en) * | 2009-08-13 | 2010-01-13 | 成都顺道医药开发有限公司 | Preparation method of sodium ascorbyl phosphate oral solution |
| CN102038704A (en) * | 2009-10-22 | 2011-05-04 | 北京颐悦医药科技有限公司 | Pharmaceutical composition for treating cold in children and preparation method thereof |
| CN106390102A (en) * | 2016-11-30 | 2017-02-15 | 郑州仁宏医药科技有限公司 | Western medicine composition for treating schizophrenia |
| CN107982213A (en) * | 2017-11-30 | 2018-05-04 | 广西壮族自治区农业科学院农产品加工研究所 | A kind of preparation method of banana flowers polysaccharide oral liquid for decreasing blood sugar |
| CN108158990A (en) * | 2018-03-07 | 2018-06-15 | 孙奉生 | The production technology of Pitavastatin Ca oral liquid |
Non-Patent Citations (1)
| Title |
|---|
| 侯淑贤，等: "氟桂利嗪口服液的人体相对生物利用度研究", 《同济医科大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106478500A (en) | Carboxylic acid-substituted（Miscellaneous）Aromatic ring analog derivative and its production and use | |
| CN106008488A (en) | Cyan indoles derivative and preparation method and use thereof | |
| US20160159745A1 (en) | Preparation of (-)-huperzine a | |
| CN104546807A (en) | Olanzapine oral fast dissolving film preparation | |
| CN109748873A (en) | The purposes of compound and its treating cancer | |
| CN104784157A (en) | Stable Montelukast oral film preparation | |
| CN108324685A (en) | A kind of production technology of flunarizine hydrochloride oral administration solution | |
| CN106905236B (en) | Blonanserin and preparation method thereof | |
| CN105566314A (en) | Tizanidine hydrochloride compound | |
| ES2224175T3 (en) | PHARMACEUTICAL GRANULES. | |
| CN104721166A (en) | Butylphthalide liquid hard capsule preparation and preparation method thereof | |
| CN111233877B (en) | Galanthamine pamoate and preparation method thereof | |
| CN104086544A (en) | Apixaban monohydrate as well as preparation method and medicinal composition thereof | |
| CN104151291A (en) | Preparation method for benzoic acid alogliptin polycrystalline type crystal | |
| JPWO2014175303A1 (en) | Crystalline polymorph α of levonorgestrel and method for producing the same | |
| CN108863765B (en) | Preparation method of loxoprofen sodium crystal | |
| CN101723904B (en) | 4-cyano-diaryl pyridine derivatives as well as preparation methods and applications thereof | |
| CN106138043A (en) | A kind of Candesartan compound of double action | |
| CN103214459A (en) | Pantoprazole sodium crystalline compound, pharmaceutical composition and preparation method thereof | |
| CN101759599B (en) | Tetracycline compound with amino isonitroso | |
| CN102344482A (en) | Betulinol derivant, preparation method and usage | |
| CN106045967A (en) | Substituted heterocyclic compounds and application of same to medicines | |
| KR101236528B1 (en) | Sealed hardcapsule containing liquid composition of dexibuprofen | |
| CN109481420A (en) | A kind of mecobalamin sustained-release capsule | |
| CN105712994A (en) | Imidazolone-morphinan as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180727 |